Epidemiology of sarcopenia: Prevalence, risk factors, and consequences
- PMID: 36907247
- DOI: 10.1016/j.metabol.2023.155533
Epidemiology of sarcopenia: Prevalence, risk factors, and consequences
Abstract
Sarcopenia is a geriatric condition featured by a progressive loss of muscle mass and function and associated with various adverse health outcomes. In this review, we aimed to summarize the epidemiological features of sarcopenia as well as consequences and risk factors of the disease. We performed a systematic review of meta-analysis on sarcopenia to collect data. The prevalence of sarcopenia varied between studies and depending on definition used. Sarcopenia was estimated to influence 10 %-16 % of the elderly worldwide. The prevalence of sarcopenia was higher among patients compared to general populations. The prevalence of sarcopenia ranged from 18 % in diabetic patients to 66 % in patients with unresectable esophageal cancer. Sarcopenia is associated with a high risk of a wide range of adverse health outcomes, including poor overall and disease-progression free survival rate, postoperative complications, and longer hospitalization in patients with different medical situations as well as falls and fracture, metabolic disorders, cognitive impairment, and mortality in general populations. Physical inactivity, malnutrition, smoking, extreme sleep duration, and diabetes were associated with an increased risk of sarcopenia. However, these associations were mainly based on non-cohort observational studies and need confirmation. High-quality cohort, omics, and Mendelian randomization studies are needed to deeply understand the etiological basis of sarcopenia.
Keywords: Meta-analysis; Muscle mass; Prevalence; Review; Risk factors; Sarcopenia.
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors have no conflict of interest to declare.
Comment in
-
Response to letter by Muralidhar and Madhivanan: Clarity and quality assessment of epidemiology of sarcopenia: Prevalence, risk factors, and consequences.Metabolism. 2023 Jul;144:155560. doi: 10.1016/j.metabol.2023.155560. Epub 2023 Apr 15. Metabolism. 2023. PMID: 37068602 No abstract available.
-
Letter to the Editor: Clarity and quality assessment of epidemiology of sarcopenia: Prevalence, risk factors, and consequences.Metabolism. 2023 Jul;144:155561. doi: 10.1016/j.metabol.2023.155561. Epub 2023 Apr 17. Metabolism. 2023. PMID: 37075859 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
